Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)
- Sponsor
- Haruhiko Fukuda
- Study ID
- NCT00147121
- Phase
- PHASE2/PHASE3
- Status
- Completed
Conditions
- Lymphoma, B-Cell
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - 69 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab + Standard CHOP — DRUGRituximab + Standard CHOP
- Rituximab + Bi-weekly CHOP — DRUGRituximab + Bi-weekly CHOP
Study Details
To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma
Key Dates
- Start date
- Sep 30, 2002
- Status verified
- Sep 2016
- Primary completion
- Feb 28, 2010
- Completion
- Feb 28, 2010
Study Design
- Enrollment
- 300 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: 1Rituximab+Standard CHOP
- Experimental: 2Rituximab+bi-Weekly CHOP
Primary Outcome Measure
CR rate (phase II) [ Time Frame: during the study conduct ]
Related Studies
- Family Study of Lymphoproliferative DisordersRecruiting · Mayo Clinic · Rochester, Minnesota
- Study of CAR-T Therapy in Older PatientsRecruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- Retreatment With CTL019/CTL119PHASE1 · Not Yet Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaPHASE1 · Recruiting · Celgene · Birmingham, Alabama